The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; Ferring; Janssen-Cilag
Consulting or Advisory Role - Astellas Pharma; Bayer; MDxHealth; OPKO Health
Research Funding - Sandoz
Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.
 
Marco Bandini
No Relationships to Disclose
 
Alberto Briganti
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Horizon Pharma; Inovio Pharmaceuticals; Lilly; Merck Sharp & Dohme; Novartis; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)
 
Guenter Niegisch
Honoraria - Roche Pharma AG
Consulting or Advisory Role - Bristol-Myers Squibb; IMS Health; Roche Pharma AG
Research Funding - 4SC
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Pfizer; Roche
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Churchill Pharmaceuticals; EMD Serono; Genentech/Roche; Incyte; Janssen; Lilly; Merck
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen (Inst)
 
Aristotelis Bamias
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Pierre Fabre
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Neeraj Agarwal
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Sanofi (Inst)
 
Cora N. Sternberg
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Ferring; Janssen; Lilly; MSD; Novartis
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Christine Theodore
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Agensys; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EMD Serono; Inovio Pharmaceuticals; Lilly; Merck; Roche/Genentech; Sanofi; Seagen
Research Funding - Agensys (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Joaquim Bellmunt
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Bristol-Myers Squibb; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck
 
Francesco Montorsi
No Relationships to Disclose
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche